| MA, Brigette |
| Active, not recruiting | 1/2 | 323 | US, RoW | FLX475, pembrolizumab (KEYTRUDA®) | RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC | Advanced Cancer | 09/24 | 01/25 | | |
| WONG, Vincent W |
| Not yet recruiting | N/A | 1800 | Europe, RoW | Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS) | PharmaNest, Inc, Chinese University of Hong Kong, University of Edinburgh, University of Seville, Imperial College London, Icahn School of Medicine at Mount Sinai, Fundacio Clinic Barcelona, Sorbonne University, Newcastle University | Metabolic Dysfunction-associated Steatotic Liver Disease | 05/25 | 07/25 | | |
NCT03282305: Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD/NASH in Chinese |
|
|
| Not yet recruiting | N/A | 5000 | NA | | Great China Fatty Liver Consortium Limited, Chinese University of Hong Kong, Virginia Commonwealth University | Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | 12/28 | 12/29 | | |
| Kwok, Timothy CY |
NCT05525039: RCT of Combination Effect of Vibration Treatment and HMB Supplementation on Myosteatosis and NMJ Degeneration |
|
|
| Recruiting | N/A | 200 | RoW | Low-magnitude High-frequency Vibration, Vibration Treatment, β-hydroxy β-methylbutyrate (HMB) supplement, Protein supplement | Chinese University of Hong Kong, Abbott | Sarcopenia, Connective Tissue Diseases in Old Age, Musculoskeletal Abnormalities | 10/24 | 04/25 | | |
| Chan, Juliana CN |
NCT05268237: Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 1/2 | 15 | RoW | Liraglutide, Placebo | Biolingus, Chinese University of Hong Kong | Diabete Type 2 | 05/24 | 07/24 | | |
| Li, Jing |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
| Not yet recruiting | 2 | 120 | RoW | Metformin Hydrochloride tablet, Metformin, Placebo | Xuanwu Hospital, Beijing, Institute of Zoology, Chinese Academy of Sciences, Beijing Institute of Genomics, Chinese Academy of Sciences, Merck Serono Co., Ltd., China | Metformin, Aging | 09/26 | 07/28 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
FRUSICA-1, NCT03903705: : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 381 | RoW | Fruquintinib in Combination with Sintilimab, Fruquintinib | Hutchmed | Advanced Solid Tumor | 12/25 | 12/25 | | |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
NCT06025045: Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments |
|
|
| Recruiting | N/A | 50 | RoW | | Jing Li, Nanjing Shihejiyin Technology, Inc. | Ovarian Cancer Stage IV, Ovarian Cancer Stage III | 08/25 | 08/25 | | |
| Wang, Li Yong |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) |
|
|
| Active, not recruiting | 3 | 294 | Europe, US, RoW | AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol | Advenchen Laboratories, LLC, Advenchen Laboratories, LLC | Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma | 10/24 | 12/24 | | |
NCT06584032: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer |
|
|
| Recruiting | 3 | 412 | RoW | fruquintinib, HMPL-013, sintilimab, IBI308, paclitaxel, doxorubicin | Hutchmed | Advanced Endometrial Cancer | 01/29 | 06/29 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer |
|
|
| Recruiting | 2 | 196 | RoW | TQB2450, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Endometrial Cancer | 12/21 | 04/22 | | |
NCT04859621: Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections |
|
|
| Recruiting | 2 | 150 | RoW | Vitamin D3 4000 IU, Vitamin D3 2000 IU, Placebo, standard antibiotic therapy | Zensun Sci. & Tech. Co., Ltd. | Recurrent Urinary Tract Infection | 04/25 | 07/25 | | |
NCT05764590: A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients |
|
|
| Completed | 2 | 55 | RoW | AP-306, Sevelamer Carbonate | Alebund Pharmaceuticals | Chronic Kidney Diseases, Hyperphosphatemia | 08/23 | 09/23 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
| Not yet recruiting | 2 | 33 | RoW | TQB3616 capsule+Fulvestrant Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 05/26 | 12/26 | | |
NCT06014190: HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer |
|
|
| Recruiting | 2 | 460 | RoW | HS-20089 | Hansoh BioMedical R&D Company | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer | 12/25 | 12/27 | | |
NCT05551507: IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer |
|
|
| Recruiting | 1/2 | 150 | RoW | IN10018 in combination with PLD, IN10018 add on to PLD treatment | InxMed (Shanghai) Co., Ltd. | Platinum-resistant Ovarian Cancer | 06/24 | 12/24 | | |
NCT05186012: APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1/2 | 51 | RoW | APG-1252, Pelcitoclax, Chidamide | Ascentage Pharma Group Inc. | NHL, Adult | 09/25 | 03/26 | | |
| Recruiting | 1 | 105 | RoW | ICP-248 | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/24 | 10/26 | | |
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia |
|
|
| Completed | 1 | 46 | US, RoW | APG2575 400 mg, APG2575 600 mg, APG2575 800 mg | Ascentage Pharma Group Inc. | Waldenstrom Macroglobulinemia | 02/24 | 02/24 | | |
NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML |
|
|
| Recruiting | 1 | 198 | RoW | LP-108, Azacitidine | Guangzhou Lupeng Pharmaceutical Company LTD. | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 12/24 | 12/25 | | |
NCT05119647: A Single-Arm Objective Performance Criteria Trial for Intracranial Thrombus Aspiration Catheter |
|
|
| Completed | N/A | 124 | RoW | Thrombus Aspiration Catheter(Ton-bridgeMT) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Acute Ischemic Stroke | 08/22 | 11/22 | | |
| Ong, Michael K |
| Recruiting | 2 | 16 | Canada | Durvalumab, (MEDI4736), Immune Modulating Radiation, Neoadjuvant Immune Modulating Radiation | Ottawa Hospital Research Institute, Cross Cancer Institute, Hamilton Health Sciences Corporation, London Health Sciences Centre, Ontario Institute for Cancer Research, AstraZeneca, Ozmosis Research Inc. | Bladder Cancer | 10/23 | 11/24 | | |
| Terminated | N/A | 119 | Europe, Canada, US, RoW | Arthroscopic rotator cuff repair with REGENETEN™ Bioinductive Implant augmentation, Arthroscopic rotator cuff repair, Arthroscopic rotator cuff repair for revision surgery | Smith & Nephew, Inc. | Rotator Cuff Injuries | 10/23 | 10/23 | | |
CORI RCT UKA, NCT04797897: Study to Evaluate the Safety and Effectiveness of REAL INTELLIGENCE™ CORI™ in Unicondylar Knee Arthroplasty (UKA) Procedures |
|
|
| Recruiting | N/A | 140 | RoW | CORI, Conventional | Smith & Nephew, Inc. | Non-inflammatory Degenerative Joint Disease, Including Osteoarthritis, Avascular Necrosis, Requires Correction of Functional Deformity, Requires Treatment of Fractures That Were Unmanageable Using Other Techniques | 11/26 | 01/27 | | |
| Khashab, Mouen |
NCT03259763: EUS-GE vs ES for Palliation of Gastric Outlet Obstruction |
|
|
| Recruiting | N/A | 112 | Europe, Canada, US, RoW | Lumen-apposing metal stent, Self-expandable metal stent | Johns Hopkins University, Boston Scientific Corporation | Gastric Outlet Obstruction | 10/25 | 08/26 | | |
| Yan, Bryan P |
| Terminated | 1/2 | 5 | RoW | YQ23, Matching placebo | New Beta Innovation Limited | Critical Limb Ischemia | 08/23 | 08/23 | | |
| Recruiting | N/A | 376 | Europe, US, RoW | SELUTION SLR™ DEB 014, Plain (Uncoated) Balloon Angioplasty (PTA) | MedAlliance, LLC, NAMSA, Cordis Corporation | Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities | 06/27 | 07/29 | | |
| Recruiting | N/A | 300 | Europe, US, RoW | SELUTION SLR™ 018 DEB, Plain (Uncoated) Balloon Angioplasty (PTA) | MedAlliance, LLC, NAMSA, Cordis Corporation | Peripheral Arterial Disease, Superficial Femoral Artery Stenosis | 08/25 | 12/29 | | |
| Zhang, Tao |
PIONEER, NCT05029453: Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy |
|
|
| Not yet recruiting | 4 | 60 | RoW | Apatinib | Wuhan Union Hospital, China, Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer, Randomized Controlled Study | 12/22 | 03/23 | | |
UNION, NCT04928807: Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 3 | 231 | RoW | Short course radiotherapy sequential camrelizumab and chemotherapy | Wuhan Union Hospital, China, Jiangsu HengRui Medicine Co., Ltd. | Rectal Cancer | 03/23 | 03/26 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT06753890: Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern) |
|
|
| Not yet recruiting | 3 | 520 | RoW | Changkang granules, Changkang Granules placebo | Tasly Pharmaceutical Group Co., Ltd | Diarrhea-predominant Irritable Boewl Syndrome | 11/26 | 12/26 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
NCT05844150: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC |
|
|
| Recruiting | 2/3 | 445 | RoW | PM8002, Platinum, Atezolizumab, Etoposide | Biotheus Inc. | SCLC | 06/25 | 12/25 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06487429: Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer |
|
|
| Recruiting | 2 | 28 | RoW | Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab | Wuhan Union Hospital, China, RemeGen Co., Ltd. | Gastric Cancer | 05/26 | 05/28 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
NCT06111274: A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 82 | RoW | Pimicotinib (ABSK021), Gemcitabine, nab-Pacilitaxel, Toripalimab | Abbisko Therapeutics Co, Ltd | Advanced Pancreatic Cancer | 12/25 | 12/26 | | |
NCT06266143: A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | 1/2 | 71 | RoW | Y101D | Wuhan YZY Biopharma Co., Ltd. | Advanced Pancreatic Adenocarcinoma | 07/24 | 12/24 | | |
NCT05653180: IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer |
|
|
| Recruiting | 1/2 | 20 | RoW | IBI310, sintilimab, IBI308 | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Biliary Tract Cancer | 12/23 | 06/24 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
| Recruiting | 1/2 | 364 | RoW | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies | Jiangsu HengRui Medicine Co., Ltd. | HER2-expressing Advanced Solid Tumors | 11/26 | 12/26 | | |
NCT06144385: A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 20 | RoW | CAR-GPC3 T cells, JWCAR204 | Shanghai Ming Ju Biotechnology Co., Ltd. | Liver Carcinoma, Hepatic Cell Carcinoma | 03/24 | 12/24 | | |
NCT06166472: A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor |
|
|
| Not yet recruiting | 1 | 72 | RoW | AK132 | Akeso | Advanced Malignant Solid Tumor | 04/26 | 07/26 | | |
NCT05169697: A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors |
|
|
| Completed | 1 | 6 | RoW | A:YH002+YH001, B:YH002+YH001, YH002+YH001 | Eucure (Beijing) Biopharma Co., Ltd | Advanced Solid Tumor | 07/23 | 07/23 | | |
NCT05441046: Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 120 | RoW | Genakumab, Tislelizumab | GeneScience Pharmaceuticals Co., Ltd. | Malignant Solid Tumors | 06/24 | 03/25 | | |
| Recruiting | 1 | 556 | RoW | IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 06/25 | 12/26 | | |
| Chan, Shannon M |
| Completed | N/A | 290 | Canada, Japan, US, RoW | Endoscopic clip placement in the gastrointestinal tract. | Boston Scientific Corporation | Hemostasis, Perforation Colon, Feeding Tube Complication, Endoscopy | 08/24 | 08/24 | | |
| Lam, Thomas Yuen Tung |
NCT06188260: Efficacy of a New Nanoemulsion Artificial Tear Targeting Dry Eye Disease |
|
|
| Completed | 2 | 31 | RoW | Systane COMPLETE Lubricant Eye Drops, Alcon limited | The Hong Kong Polytechnic University, Alcon Research | Dry Eye Syndromes | 11/24 | 11/24 | | |
| Chan, Joseph Yat Sun |
NCT06048731: Enlighten Study: The EV-ICD Post Approval Registry |
|
|
| Recruiting | N/A | 1000 | Europe, Canada, US, RoW | Defibrillation using EV-ICD | Medtronic | Ventricular Arrhythmia, Tachycardia | 05/30 | 10/37 | | |
| Lee, Jenny |
| Active, not recruiting | 2 | 171 | Europe, US, RoW | eftilagimod alpha, IMP321, efti, eftilagimod alfa, pembrolizumab (KEYTRUDA®), MK-3475 | Immutep S.A.S., Merck Sharp & Dohme LLC | HNSCC | 03/24 | 03/25 | | |
|
| Recruiting | 2 | 27 | RoW | Pembrolizumab, External Beam Radiation Therapy, Radical Neck Dissection | Queensland Health, Merck Sharp & Dohme LLC | Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer | 06/25 | 06/27 | | |
| Li, Amy |
| Active, not recruiting | 2 | 121 | Europe, Canada, US | CTL019 | Novartis Pharmaceuticals, Children's Oncology Group | B-Cell Acute Lymphoblastic Leukemia | 10/27 | 10/27 | | |
|
| Cheung, Siu Tim |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
| Lau, Becky |
| Not yet recruiting | N/A | 280 | Europe, Canada, US, RoW | Aquablation Therapy, Radical Prostatectomy | PROCEPT BioRobotics | Localized Prostate Cancer | 07/27 | 01/37 | | |
NCT06051942: PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs |
|
|
| Recruiting | N/A | 125 | US, RoW | Robotic Waterjet Treatment, Aquablation therapy | PROCEPT BioRobotics | Benign Prostatic Hyperplasia, Localized Prostate Cancer | 08/25 | 05/26 | | |
| LAU, Sui Yan |
| No trials found |
| MIU, Anki |
| No trials found |
